Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy (IMPACT on IMT): A Randomized, Multicenter, Multinational Study.

Trial Profile

Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy (IMPACT on IMT): A Randomized, Multicenter, Multinational Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Cilostazol (Primary) ; Probucol (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Embolism and thrombosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms IMPACT-on-IMT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 19 May 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top